AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01649310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: Exercises on the platform will be made in semi-squat position, static. In the first month training will be held for 10 minutes for the exercises on the platform, 30 seconds of vibration of low intensity, interspersed with rest 60 seconds while standing beside the platform. In the second month training will be held for 15 minutes, lasting 60 seconds of vibration and 30 seconds of rest in standing beside the platform. For the first two weeks training will have low intensity and the last two weeks training will have higher vibration. In the third month, training will be held for 20 minutes, 60 seconds of vibration and 30 seconds of rest while standing beside the platform. The intensity of the vibration will be high.
Study NCT02947906 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00782691 — intervention group
Intervention type: OTHER
Intervention: CT-FDG/PET scan of the head-and-neck region
Description: CT-FDG/PET scan of the head-and-neck region
Study NCT03652584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Study NCT00176475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Patients will receive a single day infusion of standard dose rituximab (375 mg/m2) on days -1, 6, 13, 20 approximately every 4 months (in conjunction with alternating doses of the lymphocyte infusion).
Study NCT00176475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: The product will then be assigned to the specific patient and the released product will be transported to and administered to the patient at CINJ, after premedication of the patient with acetaminophen 650 mg PO and diphenhydramine- HCl 25 mg PO. Blood product administration will be every 8 weeks and undertaken according to CINJ standard procedures
Study NCT00337285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyvanse (lisdexamfetamine dimesylate), NRP104
Description: NRP104 capsule once-a-day orally beginning at 30mg/day and titrated by 20 mg per day at weekly intervals up to a maximum daily dose of 70 mg
Study NCT03023202 — intervention group
Intervention type: OTHER
Intervention: PMMTB (Precision Medicine Molecular Tumor Board)
Description: PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.
Study NCT04570254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient. Protect from light at all times, as it is photosensitive.
Study NCT04570254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E. 800 mg tablet. 800 mg dose every 24 hours. Dissolve the capsule in 30 ml of hot water. The administration of vitamin E is recommended during or after meals since its absorption depends on pancreatic enzymes' presence.
Study NCT04570254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin Tablet 5 mg. A dose of 50 mg every 24 hours. Grind the 10 5 mg melatonin tablets (50 mg), levitate with 50 mL of Ora-plus (Transferring to a beaker with a magnetic stirrer). Maintain gentle agitation. Rinse the mortar with 10 mL of Ora-sweet. Add 30 mL of Ora sweet to the glass where the mixture is being made. Makeup with Ora-sweet cbp 100 mL Place label FL02 with legend Melatonin 50 mg / 20 mL. Protected from light (Dispense in a black bag that covers the transparent bag of the preparation)'s primary packaging) Give after breakfast.
Study NCT04570254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: N-acetylcysteine. Tablets, 600 mg. 600 mg dose every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient.
Study NCT04570254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours. The tablet is dissolved in 30 ml of water and is administered orally or nasogastric tube.
Study NCT00207233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MCT oil hypocaloric liquid diet
Description: The MCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 34 grams MCT oil (Life Enhancement Products, Inc. Petaluna, CA; 8.3 kcal/gm) added per day to the HMR shakes.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study.
Study NCT00207233 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: LCT hypocaloric liquid diet
Description: The LCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 31.5 grams LCT oil (corn oil; 9 kcal/gm) per day. Both diets will be isocaloric (1083 kcal/day) consisting of 38% CHO, 28% pro, 34% fat.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study.
Study NCT00207233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous abdominal adipose tissue biopsy
Description: Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.~This will be performed at baseline, 6 weeks, and 12 weeks.
Study NCT00207233 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous abdominal adipose tissue biopsy
Description: Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.~This will be performed at baseline, 6 weeks, and 12 weeks.
Study NCT03206476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional intervention based on the SCT and the TM
Description: Nutritional workshop based on the Cognitive Social Theory and the Transtheorical Model: twelve group sessions (one per week) lasting 40 minutes each, aimed at adolescents; With delivery of printed material to work at home (workbook); And two sessions (every month and a half) addressed to parents.
Study NCT03206476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional information
Description: Three informative sessions of 25 minutes (one each month) on healthy eating habits and delivery of educational material to adolescents.
Study NCT04335747 — intervention group
Intervention type: OTHER
Intervention: COVID-19 infection
Description: Hospitalisation due to a confirmed COVID-19 infection
Study NCT02895334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyHeartBaby Program
Description: Participating Caregivers will receive an electronic tablet loaded with a telemedicine intervention program (MyHeartBaby) to support caregivers remotely in the daily care and adjustment to having an infant with chronic medical needs with video-based telemedicine support services. There are a total of six sessions occurring at weeks 3, 6, 9, 12, and 15 of the study.
Study NCT03104777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviourally Informed Intervention Materials
Description: The intervention consists of 7 separate components. The intervention components are to be delivered at three time-points (referred to as bundles). The bundles consist of:~Bundle 1a - Letter to parents of children bringing a packed lunch to school, 'spot the difference' lunch box tag (attached to all lunchboxes) and a Handy Swaps Card.~Bundle 1b - Letter to parents of children only having school meals and a Handy Swaps Card.~Bundle 2 - Lunch box mixer with ideas for creating nutritious packed lunches. Bundle 3 - Shopping list, packed lunch planner and reward chart to support planning and monitoring progress.
Study NCT05773027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE
Description: SAFE includes a motivational interviewing session addressing alcohol use and risk for sexual aggression, a workshop addressing alcohol use and sexual aggression, and a booster session review.
Study NCT05773027 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Control Condition
Description: The program includes the same amount of contacts as SAFE, including an individual session focused on mindfulness and stress, a group session, and a booster session review.
Study NCT03652584 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Study NCT02600767 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Artemether-lumefantrine combination
Description: This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.
Study NCT03774134 — intervention group
Intervention type: PROCEDURE
Intervention: Complete mesocolic excision
Description: Based on the principles of CME. The inferior mesenteric artery (IMA) was divided at its origin from the aorta to perform central lymph nodes dissection along the IMA between the aorta and the branching of the left colic artery. Sigmoid resection included the complete sigmoid colon and resection of the upper part of the rectum to ensure sufficient perfusion of the colo-rectal anastomosis. To achieve sufficient distance at the proximal bowel resection margin, parts of the descending colon or even left hemicolectomy were performed at the surgeon's discretion.
Study NCT03774134 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional colon resection
Description: The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
Study NCT02214862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F18]-FDDNP
Description: radiopharmaceutical tracer
Study NCT00623051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Male Circumcision
Study NCT03906851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity and diet
Description: Physical activity: use of physical activity in theoretical subjects (3 x 30 min/week), physically active breaks (5 x 5 min/week), physical education (2 x 45 min/week) Nutrition: focus on school meals
Study NCT03059251 — intervention group
Intervention type: BIOLOGICAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered as intravenous infusion for 6 cycles (28 days per cycle): 100 milligrams (mg) on day 1 Cycle 1, 900 mg on day 2 Cycle 1, 1000 mg on days 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6.
Study NCT01164917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG811
Description: Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.
Study NCT01164917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG811 Placebo
Description: 8 subjects will be randomized to receive AMG 811 Placebo in Period 1 and will receive AMG 811 in Period 2. The AMG 811 Placebo and AMG 811 will be administered by injection
Study NCT04066777 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: alcohol septal ablation
Description: injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
Study NCT02721303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3-day diet Run-in
Description: Participants will be studied on one occasion after a 3-day diet run-in. This will be followed by a breakfast meal.
Study NCT02721303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: After a 3-day diet run-in, participants will undergo a functional magnetic resonance imaging procedure (fMRI). Repeat fMRI will be performed 30 minutes after the meal.
Study NCT02264964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GamCath®
Description: Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in femoral vein.
Study NCT02264964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula creation
Description: 500 patients will undergo AVF creation in either arm for femoral vein catheterization group.
Study NCT02264964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GamCath®
Description: Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in right internal jugular vein.
Study NCT02264964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula creation
Description: 900 patients will undergo AVF creation in left arm for internal jugular vein catheterization group.
Study NCT01470664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FST-100
Description: 0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)
Study NCT01470664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FST-100 (Component #1)
Description: 0.6% PVP-Iodine ophthalmic solution alone
Study NCT01470664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FST-100 Vehicle
Description: FST-100 Vehicle
Study NCT03703349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium sulfate will be prescribed by the surgeon / Anesthesiologist and will be taken orally by the patient for the 3 days preceding the surgery
Study NCT03703349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo for Magnesium
Study NCT03179774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization
Description: All interventions will be performed via 8F femoral sheath. Target common carotid artery will be engaged with 8F JR 4 guiding catheter. Intra-luminal wiring using coronary guidewires and microcatheters or alternative subintimal tracking with antegrade re-entry technique. Wiring would be abandoned after 30 minutes of futile effort, consumption of more than 300 ml of contrast, or when the wire tip is confirmed to be extravascular. Once wire enters distal true lumen, the microcatheter was exchanged to a 1.5 mm diameter coronary balloon for pre-dilatation. Distal embolic protection device would be deployed if an adequate landing zone can be identified. Properly sized balloon expandable stents and self-expanding stents were then deployed to scaffold the occlusion. Balloon post-dilatation may be done if stent expansion was inadequate.
Study NCT02428816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI acquisition
Description: MRI acquisitions
Study NCT02428816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral evaluations
Description: Evaluations about motor abilities, sleep, cognition and lifestyle
Study NCT02690493 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, three times a week, during twelve sessions.
Study NCT02690493 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Taping
Description: Elastic taping is positioned directly on the skin (on the back of the fingers, hand, forearm and arm - paretic upper limb), three times a week, during twelve sessions. The patient should keep the taping on the skin for two days.
Study NCT02690493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and Functional Taping
Description: Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, then elastic taping is positioned directly on skin (on the back of the fingers, hand, forearm and arm - paretic upper limb). Both procedures are performed three times a week, during twelve sessions.
Study NCT02721303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous catheter placed for blood draws
Description: On the study day participants will present in the fasting state, have an intravenous catheter placed for blood draws and have baseline blood samples taken. Blood and appetite measures will be performed every half hour for 3 hours.
Study NCT00523549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: 160 mg or 320 mg tablets once a day
Study NCT00523549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Description: 5 mg or 10 mg tablets once a day
Study NCT03463577 — intervention group
Intervention type: OTHER
Intervention: Safety assessment following routine immunization with Boostrix
Description: Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.
Study NCT01550107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: 300mg b.d for 24 weeks
Study NCT01550107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose tablets
Description: matched placebo tablets b.d
Study NCT02952872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Tablet-based Intervention to Address Heavy Alcohol Use
Description: The intervention will be be tablet-based and take approximately 20 minutes to complete. Content will focus on heavy alcohol use.
Study NCT03987490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Vaccine reminder notification sent via text
Study NCT03864666 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol 100 mg
Description: One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
Study NCT03987490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PostCard
Description: Vaccine reminder notification sent via standard mail
Study NCT03987490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: No additional information given to parents
Study NCT03987490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: Phone-based semi-guided discussion with parents who had not yet agreed to vaccination after reminders sent
Study NCT04493697 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental 1
Description: A ThermoNeuroModulation device will be worn by the participant that delivers warm waveforms in one ear (42 °C) and cool waveforms (17 °C) in the other ear.
Study NCT04493697 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Experimental 2
Description: A ThermoNeuroModulation device will be worn by the participant that will neither warm nor cool.
Study NCT06380647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Acyclovir
Description: Patients were observed for developing signs of eczema herpeticum and Tzanck smear was done every 10th day and first follow up at OPD after 7days of discharge following ward management protocol. If prophylactic acyclovir was efficacious then no eczema herpeticum developed. Patients who develop eczema herpeticum were isolated and were treated with injection acyclovir 15 to 30 mg/kg/day into three divided doses for 10 to 14 days.
Study NCT06380647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Acyclovir
Description: Patients were observed for developing signs of eczema herpeticum and Tzanck smear was done every 10th day and first follow up at OPD after 7days of discharge following ward management protocol. If prophylactic acyclovir was efficacious then no eczema herpeticum developed. Patients who develop eczema herpeticum were isolated and were treated with injection acyclovir 15 to 30 mg/kg/day into three divided doses for 10 to 14 days.
Study NCT00292981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 Esterase Inhibitor
Description: Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
Study NCT02153190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYBRID
Description: During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.
Study NCT02153190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPEN
Description: During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
Study NCT05470959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ACTIVA bioactive
Description: bioactive ionic resin composite